Rituximab therapy in malignant lymphoma

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Rituximab is the first approved monoclonal antibody for B-cell lymphoma treatment.
• It has demonstrated significant activity in various B-cell lymphomas, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
• Rituximab offers a favorable activity and toxicity profile, improving patient outcomes.

Purpose of the Study:

• To review the efficacy and impact of rituximab in treating B-cell lymphomas.
• To highlight the effectiveness of rituximab combined with chemotherapy (R-CHOP).
• To acknowledge the challenge of rituximab refractoriness in some patients.

Main Methods:

• Review of randomized and non-comparative studies on rituximab in B-cell lymphomas.
• Analysis of clinical trial data for rituximab and R-CHOP combination therapy.
• Discussion of observed patient responses and treatment outcomes.

Main Results:

• Rituximab shows activity across multiple B-cell lymphoma types, including untreated and relapsing cases.
• The combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) exhibits superior efficacy in DLBCL and FL.
• Despite its success, a subset of patients exhibits refractoriness to rituximab therapy.

Conclusions:

• Rituximab has revolutionized B-cell lymphoma management due to its high efficacy and low toxicity.
• R-CHOP is the most effective chemotherapy regimen for DLBCL and FL.
• Further research is needed to understand the mechanisms underlying rituximab resistance.